BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 15828547)

  • 1. Letrozole improves disease-free survival vs tamoxifen in adjuvant treatment of early breast cancer.
    Oncology (Williston Park); 2005 Mar; 19(3):277, 360. PubMed ID: 15828547
    [No Abstract]   [Full Text] [Related]  

  • 2. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
    Ingle JN; Tu D; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Goss PE
    Breast Cancer Res Treat; 2006 Oct; 99(3):295-300. PubMed ID: 16541302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE; El-Ouagari K; Karnon J; Sofrygin O
    Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
    Mouridsen H; Sun Y; Gershanovich M; Perez-Carrion R; Becquart D; Chaudri-Ross HA; Lang R
    Oncologist; 2004; 9(5):489-96. PubMed ID: 15477633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Koeberle D; Thuerlimann B
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):5-10. PubMed ID: 16375638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM
    Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
    Baum M
    Eur J Cancer; 2005 Aug; 41(12):1667-77. PubMed ID: 16046117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extending the benefits of adjuvant therapy in early HR+ breast cancer.
    Goss PE
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():45-52. PubMed ID: 18785006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].
    Forciniti S
    Suppl Tumori; 2004; 3(4):S25-6. PubMed ID: 15206205
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.